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Abstract: HIV-1 infection afflicts more than 35 million people worldwide, according to 
2014 estimates from the World Health Organization. For those individuals who have access 
to antiretroviral therapy, these drugs can effectively suppress, but not cure, HIV-1 infection. 
Indeed, the only documented case for an HIV/AIDS cure was a patient with HIV-1 and acute 
myeloid leukemia who received allogeneic hematopoietic cell transplantation (HCT) from 
a graft that carried the HIV-resistant CCR5-∆32/∆32 mutation. Other attempts to establish a 
cure for HIV/AIDS using HCT in patients with HIV-1 and malignancy have yielded mixed 
results, as encouraging evidence for virus eradication in a few cases has been offset by poor 
clinical outcomes due to the underlying cancer or other complications. Such clinical strate-
gies have relied on HIV-resistant hematopoietic stem and progenitor cells that harbor the 
natural CCR5-∆32/∆32 mutation or that have been genetically modified for HIV-resistance. 
Nevertheless, HCT with HIV-resistant cord blood remains a promising option, particularly 
with inventories of CCR5-∆32/∆32 units or with genetically modified, human leukocyte 
antigen-matched cord blood.
Keywords: curing HIV infection, hematopoietic cell transplantation, genetic modification of 
stem cells, CCR5 mutation, CCR5-∆32/∆32 cord blood inventory
Introduction and background
Antiretroviral therapy (ART) inhibits various stages in the viral life cycle, reduces 
the rates of transmission, and improves life expectancy. Unfortunately, ART is non-
curative, and nearly all HIV-infected individuals must adhere to daily drug regimens 
for the entirety of their lives. This requirement indefinitely prolongs issues such as 
drug resistance, adverse effects, and cost.1 While ART extends and improves the 
quality of life, it does not fully restore health. Individuals on ART can experience 
chronic inflammation, immunosenescence, bone density loss, premature aging, 
and increased non-AIDS morbidity and mortality.2 ART treatment interruptions in 
aviremic HIV-infected individuals lead to rapid viral recrudescence that reaches 
pretreatment levels.3 Thus, suppression of viral replication with ART does not eradi-
cate the virus, as long-lived resting memory CD4+ T-cells can harbor latent virus, 
and while various reservoirs may produce low-levels of virus, such as microglia and 
astrocytes in the central nervous system, tissue-derived dendritic cells, macrophages, 
and natural killer cells.4 Further complicating matters, latently infected T-cells may 
undergo clonal expansion by homeostatic proliferation,5 while infected T-cells and 
macrophages can persist without undergoing apoptosis or cytotoxic T-lymphocytes 
(CTL)-induced killing.6,7
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Due to persistence of infection during ART, alternative 
therapeutic strategies are being explored to establish a cure 
for HIV-1. Current and emerging approaches to eradicate 
HIV include transplanting virus-resistant hematopoietic 
stem and progenitor cells (HSPCs) in an effort to generate 
an HIV-resistant immune system. To achieve HIV resis-
tance, much focus has been placed on natural mutation of or 
engineered inhibition of the endogenous chemokine recep-
tor CCR5.8 Owing to the role of CCR5 as a co-receptor for 
HIV entry in CCR5+ CD4+ T-cells, homozygous carriers 
of a 32-bp deletion in the CCR5 gene (CCR5-∆32/∆32) 
are naturally resistant to HIV.9,10 As an alternative to using 
allogeneic CCR5-∆32/∆32 HSPCs from human leuko-
cyte antigen (HLA)-matched adult or cord blood donors 
who have this homozygous mutation, genome editing 
or gene therapy strategies aim to use therapeutic genes 
that disrupt CCR5 genetically or post-transcriptionally, 
respectively.
Cure of Hiv infection with hematopoietic 
cell transplantation (HCT)
The only known cure of HIV infection has resulted from 
HCT. This has been accomplished by Hütter et al11 with HCT 
using peripheral blood stem cells from an HLA-matched adult 
donor who had the CCR5-∆32/∆32 mutation. The patient has 
remained without any evidence of HIV infection for more 
than 8 years after discontinuation of antiretroviral drug 
therapy, and the consensus is that he has been cured.
However, identifying a HLA-matched adult CCR5-∆32/ 
∆32 donor for a given patient is not readily feasible in part 
because the prevalence of the homozygous variant allele is 
only about 0.8%–1% of individuals of northern European 
descent12,13 and much less in other ethnic groups.14 Further, 
when an adult donor is used for a HCT, a very close HLA 
match between donor and patient is required. Accordingly, 
finding an adult donor who has a very close HLA match to 
a patient in need of a transplant and who is also homozy-
gous for the CCR5-∆32 allele is extremely difficult and 
will only rarely be possible. In contrast, cord blood CCR5-
∆32/∆32 units provide a major advantage in that much less 
stringent HLA matching is required between donor and 
patient.15
Since donor–recipient HLA matching for a cord blood 
transplant is much less stringent,15 it is evident that cure of 
HIV infections by HCT can be much more easily accom-
plished by using stem cells obtained from a modestly sized 
inventory of cryopreserved CCR5-∆32/∆32 cord blood 
units. Such an inventory has been developed at StemCyte 
International Cord Blood Center and is available for use for 
appropriate patients.
HCT using CCR5-∆32/∆32 cord blood 
units
Units from StemCyte’s inventory of CCR5-∆32/∆32 cord 
blood units have been used for allogeneic HCT in patients 
with HIV infection. One of the transplants was performed 
by Dr Rafael F Duarte in Barcelona, Spain using dual hap-
loidentical/cord blood transplantation in a patient with dif-
fuse large B-cell lymphoma and HIV infection.16 Neutrophil 
engraftment, derived from the haploidentical donor, occurred 
on day +11. The cord blood was found to have a poor clono-
genic capacity, and donor switch to cord blood origin failed, 
with a persistently low cord blood chimera of ,5% for up to 
7 weeks. A second CCR5-∆32/∆32 cord blood was infused 
on day +52, leading to a very rapid increase in chimerism 
which was from the first cord blood unit and which reached 
100% by day +73. At this point, the patient’s hematopoiesis, 
including CD4+ T-lymphocytes, became CCR5-∆32/∆32. 
Ultrasensitive plasma viral load analysis decreased soon after 
HCT, reaching minimal levels at the time of full cord blood 
chimerism. No HIV-1 DNA was detected using droplet digital 
polymerase chain reaction quantification or semiquantitative 
tests of amplification. Importantly, although recipient CD4+ 
T-cells responded to proliferation and activation stimuli, they 
were resistant to infection by the patient’s isolate as well as by 
laboratory-adapted HIV-1 strains. Unfortunately, the patient 
developed an aggressive diffuse large B-cell lymphoma pro-
gression, and following very rapid clinical deterioration, died 
from disease progression 3 months after HCT.16
In addition, as testing of cord blood units for the CCR5 
mutation was being carried out, a HCT using a unit that was 
subsequently determined to be CCR5-∆32/∆32 was pro-
vided to an adult patient with acute myelogenous leukemia 
who was not infected with HIV. This unit was transplanted 
as part of a double cord blood transplant. This unexpected 
event provided the opportunity to collect post-transplant 
data, which indicated engraftment of the CCR5-∆32/∆32 
unit as the “winning unit”. At a time when evaluation of 
chimerism indicated 100% engraftment by the CCR5-
∆32/∆32 unit, the patient’s peripheral blood mononuclear 
cells showed no significant HIV replication with in vitro 
infection with either of the laboratory strains of HIV-1, 
BAL (CCR5 tropic), or NL4-3 (CXCR tropic) compared 
with a normal control.17
Thus, in the only two instances in which we have had an 
opportunity to test the post-transplant blood specimens of 
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patients who were engrafted with CCR5-∆32/∆32 cord blood 
cells, the patients’ cells in vitro were found to be resistant 
to infection by HIV.16,17 It is possible that the HIV-infected 
patient was cured of HIV; unfortunately, his death three 
months following the transplant prevented definitive evalu-
ation of a possible cure. Nevertheless, these data strongly 
support the use of cord blood as a platform for broader 
application of this curative technology to other HIV-1 infected 
individuals.
An additional HCT was performed in Utrecht, the 
Netherlands, using a cord blood unit from StemCyte’s inven-
tory of CCR5-∆32/∆32 units. The patient was a 53-year-old 
male patient with high-risk myelodysplastic syndrome and 
HIV infection. A dual haploidentical/cord blood HCT using 
a CCR5-∆32/∆32 cord blood unit was performed after 
myeloablative conditioning.18 The patient achieved neutrophil 
and platelet engraftment as well as full cord blood chimerism. 
However, the patient developed a severe lung infection and 
a relapse of the underlying disorder and died 2 months after 
the HCT. Analyses of viral and immunological compartments 
are pending.
A separate CCR5-∆32/∆32 cord blood transplantation, 
which did not involve the StemCyte inventory, was performed 
at the University of Minnesota with a CCR5-∆32/∆32 cord 
blood unit.19 The patient was a 12-year-old male with HIV 
and acute lymphoblastic leukemia. Poor HLA-matching 
may have contributed to the fact that the patient died as a 
result of graft-versus-host disease 3 months following the 
transplant.
HCT using CCR5-∆32/∆32 units 
from adults
In addition to the Berlin patient, two other HIV/AIDS patients 
with malignancy have been transplanted using adult CCR5-
∆32/∆32 stem cells that were from an HLA-mismatched 
unrelated donor or an HLA-matched related donor. The 
patients died of infection within 4 months.19 Also, a patient 
who carried a detectable fraction of CXCR4-tropic virus 
was transplanted with a CCR5-∆32/∆32 HLA-matched 
unrelated unit.20 The patient discontinued ART before the 
initiation of myeloablative treatment but resumed therapy 
3 weeks after transplantation because of a rebound of 93,300 
copies of HIV RNA per milliliter. The genotypic analysis of 
HIV-1 variants in this case showed a shift from a dominantly 
R5-tropic HIV before transplantation toward a CXCR4-
tropic HIV after transplantation. It is unclear whether the 
coreceptor switch took place before the allogeneic transplant 
or after transplantation in the absence of retroviral drugs.20 
Nevertheless, this suggests the possibility that viral escape 
mechanisms might jeopardize CCR5-knockout strategies 
to control HIV infection. The patient died 12 months after 
transplant of relapse of non-Hodgkin’s lymphoma.
Materials and methods
Developing an inventory of CCR5-
∆32/∆32 cord blood units
Testing of large numbers of samples requires the collabora-
tion of multiple cord blood banks since no single bank has 
enough units. Specimens for testing were obtained from 
StemCyte International Cord Blood Center (hereafter referred 
to as StemCyte) and collaborating cord blood banks: MD 
Anderson Cancer Center Cord Blood Bank; the Carolinas 
Cord Blood Bank at Duke University; the St Louis Cord 
Blood Bank; the Sydney, Australia Cord Blood Bank; the 
Barcelona, Spain Cord Blood Bank; and the University of 
Colorado Cord Blood Bank.
Details of the methods used to identify specimens that 
are CCR5-∆32/∆32 have been reported earlier.17
Projections of the probability of finding an 
appropriately HLA-matched cord blood unit with an 
adequate cell dose for a patient in need of a HCT
HLA match rates for an inventory of 300 CCR5-∆32/∆32 
cord blood units were estimated with a population of HLA 
haplotype frequencies using a population genetic model 
developed by Gragert et al previously applied to project 
match rates for the Be the Match Registry® operated by 
the National Marrow Donor Program.21 The dose require-
ment for cord blood HCT was incorporated into the model 
by calculating the percentage of cords with the commonly 
used minimum adequate total nucleated cells (TNC) dose 
of 2.5×107/kg for each simulated patient based on his or her 
weight and considered matched units with inadequate dose 
as unavailable. More recently, data published by Liu et al,22,23 
Van Besien et al,24 and Kwon et al25,26 indicate that a lower 
minimum cord blood cell dose is adequate when a combined 
haploidentical and cord blood transplantation is performed. 
Accordingly, similar projections were also carried out using 
a minimum cell dose of 1×107/kg. The CCR5-∆32/∆32 units 
in the special inventory are primarily from white donors, and 
it is true that patients in need of transplantation more com-
monly find a matched donor from among those in their own 
ethnic group. To assess match rates for minority populations, 
we simulated 10,000 African American, Hispanic American, 
and Chinese American patients searching European origin 
cord inventory replicates (Table 1).
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Genetic modification of stem cells
Due to rarity of the CCR5-∆32/∆32 mutation, strategies to 
engineer HIV resistance in CD34+ HSPCs are being explored 
using gene therapy and gene-editing. These approaches 
typically aim to protect cells from viral infection with the 
expression of anti-HIV genes or with the disruption of host 
genes required for HIV entry. In such approaches, CD34+ 
HSPCs undergo ex vivo treatment with genome-editing or 
gene therapy modalities, followed by transplantation into 
the HIV/AIDS patient.
For gene therapy applications, CD34+ HSPCs are trans-
duced with an integrative vector that encodes one or more 
anti-HIV genes. From the late 1990s, several clinical trials 
were conducted to test the safety, feasibility, and effective-
ness of CD34+ HSPCs transduced with gammaretroviral 
vectors that encoded anti-HIV ribozymes,27–29 antisense 
transcripts,30 and RNA decoys.31 Due to the tendency of 
gammaretroviral vectors to integrate near and activate 
oncogenes,32 more recent approaches have utilized lentiviral 
vectors,33–37 foamy virus vectors,38–40 or transposons41 for 
transgene expression.
The first clinical study (NCT00569985) to evaluate 
a combinatorial lentiviral vector for HIV was performed 
at the City of Hope (Duarte, CA, USA) for patients with 
AIDS-related non-Hodgkin’s lymphoma. HIV-infected 
individuals received CD34+ HSCs that were engineered to 
express a variety of anti-HIV small RNAs, including a small 
interfering RNA against HIV tat/rev, an anti-CCR5 ribozyme, 
and trans-activation response element decoy.33 A related 
study (NCT01961063) will further evaluate this approach 
after pre-conditioning with busulfan, which may improve 
engraftment of transplanted cells. A different combinatorial 
lentiviral vector, which co-expresses a short hairpin RNA 
against CCR5 and HIV-1 entry inhibitor peptide C46, is being 
evaluated in a Phase I/II clinical trial (NCT01734850) in HIV/
AIDS patients, who have been exposed to ART. In this trial, 
conducted by Calimmune, Inc. (Los Angeles, CA, USA) and 
the University of California, Los Angeles, autologous CD34+ 
HSPCs and CD4+ T-cells are transduced with the vector and 
transplanted after preconditioning with busulfan.42 A pending 
study (NCT01769911) at Fred Hutchinson Cancer Research 
Center (Seattle, WA, USA) will use autologous CD34+ 
HSPCs carrying a lentiviral vector with the C46 peptide 
for patients with HIV-associated non-Hodgkin or Hodgkin 
lymphoma. The strategy has shown promise in preclinical 
studies in a pigtail macaque model for HIV.43,44
Genome-editing aims to disrupt host genes required for 
HIV entry using site-directed DNA nucleases. Site-specific 
zinc finger nucleases (ZFNs) have been designed to introduce 
destructive mutations in the CCR5 gene in an effort to eliminate 
the host co-receptors that are required for HIV infection.45–49 
The ZFN against CCR5 appears particularly promising, as 
it is currently being evaluated in autologous CD4+ T-cells in 
multiple clinical studies (NCT00842634, NCT01252641, 
NCT01044654, NCT01543152, and NCT02225665) and in a 
pending study with autologous CD34+ HSPCs.49 Transcription 
activator-like effector nucleases 50–52 and the clustered regularly 
interspaced short palindromic sequence repeats (CRISPR)/
Cas9 system50,53–55 represent different classes of gene-editing 
enzymes that may be used to target host factors to create HIV-
resistant cells.
For the genome-editing approaches, an important 
consideration is that genetic modification of heterozy-
gous CCR5∆32 cells is likely more efficient than genetic 
modification of CCR5 wildtype cells, due to the need to 
achieve biallelic and not monoallelic mutation. Thus, using 
heterozygous CCR5∆32 units for genetic modification would 
be expected to make HCT much more effective for a cure of 
HIV infection, due to the higher percentage of modified cells 
with biallelic CCR5 disruption. This concept is consistent 
with observations from a clinical study of the CCR5 ZFN in 
autologous CD4+ T-cells, in which a single patient who was 
heterozygous for CCR5∆32 had the lowest viral load peak 
and the longest delay in viral recrudescence.56
While it is impractical to restrict CCR5 genome-editing 
of autologous cells to patients who carry the heterozygous 
Table 1 Projected HLA match rates with a 300 unit inventory of 
CCR5-∆32/∆32 cord blood units
Ethnic group Adult patients Pediatric patients
Whites
includes need for TNCs of 2.5×107 cells/kg
6 of 6 matches: 0.01% 6 of 6 matches: 0.01%
5 of 6 matches: 4.5% 5 of 6 matches: 10.6%
4 of 6 matches: 27.9% 4 of 6 matches: 73.6%
includes need for TNCs of 1×107 cells/kg
6 of 6 matches: 0.09% 6 of 6 matches: 1.01%
5 of 6 matches: 10.7% 5 of 6 matches: 10.8%
4 of 6 matches: 82.1% 4 of 6 matches: 85.6%
Minority populations
includes need for TNCs of 2.5×107 cells/kg
 African American 4 of 6 matches: 9.9% 4 of 6 matches: 28.6%
 Hispanic American 4 of 6 matches: 14% 4 of 6 matches: 44.1%
 Chinese American 4 of 6 matches: 2.7% 4 of 6 matches: 12.3%
includes need for TNCs of 1×107 cells/kg
 African American 4 of 6 matches: 31.6% 4 of 6 matches: 34.1%
 Hispanic American 4 of 6 matches: 48.9% 4 of 6 matches: 52.5%
 Chinese American 4 of 6 matches: 13.9% 4 of 6 matches: 15.7
Abbreviations: HLA, human leukocyte antigen; TNCs, total nucleated cells.
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CCR5∆32 mutation, heterozygous CCR5∆32 HSPCs could 
be obtained from an HLA-matched donor or cord blood. 
Because heterozygous CCR5∆32 units are much more readily 
available than homozygous CCR5-∆32/∆32 units, develop-
ing a file of HLA typed heterozygous units is eminently 
feasible. Therefore, using genetically modified heterozygous 
CCR5∆32 cord blood units offers a practical means of pro-
viding HIV resistant cells to an HIV-infected patient. This 
is critical for members of minority populations for whom 
finding an HLA-matched unit from our inventory of ∼200 
CCR5-∆32/∆32 cord blood units is unlikely.
Thus, we are developing a file of HLA typed CCR5 
heterozygous cord blood units which will be available for 
genetic modification prior to HCT of appropriate patients. 
The major factor in our approach to curing HIV infection is 
our use of heterozygous CCR5 cord blood units, which allows 
for significantly greater efficiency of genetic modification, 
and also allows for far easier HLA matching of available 
units than does relying on the availability of the quite unusual 
homozygous CCR5-∆32/∆32 units.
Results
identifying CCR5-∆32/∆32 units  
in inventories of cryopreserved  
cord blood units
We have identified .200 CCR5-∆32/∆32 units after having 
tested samples from approximately 25,000 cryopreserved 
cord blood units obtained primarily from Caucasians for 
an incidence of about 0.8%. Testing an additional 15,000 
samples from Caucasians is expected to increase the special 
inventory to approximately 300 units. Further development of 
the special inventory is eminently feasible, since, according 
to the estimates of Gonzalez et al,14 there are approximately 
400,000 cord blood units cryopreserved around the globe, 
including 2,000–4,000 homozygous CCR5-∆32/∆32 units.
Probabilities of finding adequately 
matched cord blood units with an 
adequate cell dose in an inventory  
of 300 CCR5-∆32/∆32 cord blood units
Table 1 indicates the projected probabilities of finding 
an adequately HLA-matched unit with a TNC count of 
2.5×107/kg or with a TNC count of $1×107/kg in an inven-
tory of 300 CCR5-∆32/∆32 units for pediatric and adult white 
patients and for patients of other ethnic groups. Projected 
match rates for white patients using a minimum necessary 
TNC count of $2.5×107/kg were 27.9% for adults and 
73.6% for pediatric patients. Using a minimum necessary 
TNC count of $1.0×107/kg, the projected match rates were 
82.1% for adults and 85.6% for pediatric patients. Probable 
match rates were significantly lower for patients of minority 
ethnic groups.
The HLA match rates when using heterozygous CCR5 
units will obviously be much greater, although we have not 
calculated detailed estimates.
Discussion
Long-term control of HIV infection has been accomplished 
by Hütter et al11 with HCT using peripheral blood stem cells 
from an HLA-matched adult donor who had the CCR5-
∆32/∆32 mutation. The patient has remained without any 
evidence of HIV infection for more than 8 years after discon-
tinuation of antiretroviral drug therapy, and the consensus is 
that he has been cured. However, identifying a HLA-matched 
adult CCR5-∆32/∆32 donor for a given patient is not readily 
feasible because of the infrequency of the CCR5-∆32/∆32 
allele and the requirement for a very close HLA match 
between adult donors and patients. Since donor–recipient 
HLA matching for a cord blood transplant is much less 
stringent,15 it is evident that cure of HIV infections by HCT 
can be much more easily accomplished by using stem cells 
obtained from a modestly sized inventory of cryopreserved 
CCR5-∆32/∆32 cord blood units. Furthermore, experience 
in two cord blood transplants using CCR5-∆32/∆32 cord 
blood units obtained from our inventory has indicated that 
after establishing full cord blood chimerism, the patient’s 
grafted cells were resistant to in vitro infection of HIV.16–18 
Such data strongly support the use of cord blood as a platform 
for broader application of this curative technology to HIV-1 
infected patients.
There are several perceived problems with cord blood 
HCT: these include insufficient cell dose, a prolonged time 
to engraftment and, in double cord blood transplantation, the 
inability to predict the dominant, or “winning unit”. Double 
cord blood transplants using CCR5-∆32/∆32 cord blood units 
can be made available for some adult patients, although find-
ing two adequately HLA matched units for a patient from our 
modestly sized inventory would be unusual.
The co-infusion of adult progenitor cells, usually adult 
haploidentical cells, with cord blood stem cells, addresses 
these problems in a technically, minimally demanding 
fashion. Dual haploidentical/cord blood transplantation 
provides adequate cell dose for essentially all patients. 
Haploidentical/cord blood transplantation has been shown to 
reduce the post-transplantation period of neutropenia, mostly 
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using units with relatively low cell dose. Liu et al23 reported 
that the infused post-thaw TNC counts ranged from 1.24 to 
2.09×107/kg (median 1.55) of the patient’s body weight. The 
cord blood cell dose had no measurable impact on outcomes, 
thus making it possible to select cord blood units with lower 
cell doses than those that have generally been considered 
necessary.
Regardless of the patient and donor selection or proce-
dural differences, all groups reporting experience with dual 
haploidentical/cord blood HCT observed rapid neutrophil 
recovery with a median time of 10–11 days.18,23–25 The median 
time to platelet recovery varied among reporting groups from 
19 days to 32 days. The incidence and severity of graft-
versus-host disease were generally low but, in spite of this, 
the cumulative incidence of disease recurrence for those with 
malignant disease was moderate, ie, 17%–28% at 1 year.24 
Immune reconstitution after dual haploidentical/cord blood 
HCT was similar to that seen after cord blood transplantation, 
in spite of much lower cord blood cell doses.24,57
In dual haploidentical/cord blood HCT, the cord blood 
almost always predominates (median percentage of cord 
blood cells is 95% by day 180).23 When providing a HCT 
attempting to cure HIV, one may use a haploidentical unit 
and a single CCR5-∆32/∆32 cord blood, and have a very 
high probability that the “winning unit” will be the cord 
blood. Thus, the use of combined haploidentical and cord 
blood transplants provides important and, for some patients, 
essential advantages when considering use of HCT to cure 
HIV in adults.
The economic viability of HCT for a cure of HIV has been 
called into question and HCT has been shunned by many as 
not a plausible alternative to drug therapy. However, realistic 
estimates of the potential economic impact of HCT for HIV 
suggest that this type of treatment would be cost-effective.58 
For example, the cost of an autologous bone marrow trans-
plant ranges from $40,000 to upwards of $90,000, additional 
costs, eg, for and required product release testing, it is rea-
sonable to assume a final cost of $250,000–$300,000 per 
patient. By comparison the cost of lifelong ART therapy 
has been estimated to be as high as $420,000–$755,000. 
Thus, it appears that a one-time intervention with stem cell 
gene therapy is not outside of economic reality in developed 
countries.
Conclusion
HCT using peripheral blood stem cells from an adult donor 
having the CCR5-∆32/∆32 mutation has produced a cure of 
a HIV-infected person. However, CCR5-∆32/∆32 donors 
are quite unusual, and this coupled with the fact that the use 
of stem cells from peripheral blood and bone marrow of 
adults requires a very close HLA match between the donor 
and the recipient makes it impossible to frequently perform 
HCT using CCR5-∆32/∆32 stem cells from adult donors for 
patients in need of treatment for HIV. The less stringent HLA 
matching required using cord blood stem cells that makes the 
use of cord blood units having the CCR5-∆32/∆32 mutation, 
or that are genetically modified to be resistant to HIV infec-
tion, a much more viable approach.
A key facet of our work is providing cord blood units 
that contain stem cells that are resistant to HIV to patients 
infected with HIV. One approach has been the development 
of an inventory of CCR5-∆32/∆32 cord blood units. We 
have .200 such units in our continuously enlarging inven-
tory, and three have been used for HCT. In two instances we 
were able to test peripheral blood samples post-transplant, 
and in vitro studies indicated that the patient’s peripheral 
blood cells were resistant to HIV. This is encouraging and 
suggests that cure of HIV may be achieved using cord blood 
CCR5-∆32/∆32 cells in HCT.
We are expanding our work to include genetic modification 
of donor stem cells to make them resistant to infection by HIV. 
Previous research on genetic modification has relied on modi-
fication of wild type cells, whereas our studies will involve 
modification of the heterozygous CCR5 units that are also 
in our inventory. This approach has three major advantages 
which are the following: 1) that the genetic modification of 
heterozygous units will yield a significantly higher percentage 
of modified cells which may make HCT of HIV more effec-
tive; 2) that an inventory of HLA-typed heterozygous CCR5 
units to be used for genetic modification for a given patient can 
be developed far easier than an inventory of CCR5-∆32/∆32 
units; and 3) it will be much more feasible to find a HLA 
matched unit for members of minority populations from the 
list of heterozygous units than it is for the comparatively small 
list of homozygous CCR5 cord blood units.
No approach to a cure of HIV has been successful other 
than HCT with stem cells that are resistant to infection by 
HIV. We expect to add to the list of HCTs that have been 
successful in curing HIV.
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